Tularemia Market is accounted to be a multimillion dollar business by 2024

A report by Piramal, Alkem Labs, GlaxoSmithKline, Bayer, Sun Pharmaceutical Industries, Cipla, Zydus Cadila, LUPIN

Tularemia is an infection caused by the intracellular gram negative bacterium Francisella tularensis. It causes fever, ulceration at the site of entry and/or swelling of nearby lymph nodes.

The Global Tularemia Market is accounted for USD 161.5 million in 2016 growing at a CAGR of 3.1% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Major Market Drivers and Restraints:

  • High expenditure on the health care
  • Favorable reimbursement policies

Get Exclusive Free Sample Report at:

Competitive Analysis: Global Tularemia Market

The global tularemia market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of tularemia market for global, Europe, North America, Asia Pacific and South America.

Major Market Competitors: Global Tularemia Market

Some of the major players operating in global tularemia market are

  • Piramal
  • Alkem Labs
  • GlaxoSmithKline plc
  • Bayer
  • Sun Pharmaceutical Industries Ltd
  • Cipla Inc
  • Zydus Cadila
  • Glenmark
  • Pfizer Inc
  • Reddy’s Lab among others

Know More Business Opportunities in global tularemia market. Speak To Our Analyst And Gain Crucial Industry Insights That Will Help Your Business Expand. Request Analyst Call for More Insight

Market Segmentation: Global Tularemia Market

By type, global tularemia market is segmented into ulceroglandular tularemia, glandular tularemia, oculoglandular tularemia, oropharyngeal tularemia, pneumonic tularemia.

On the basis of diagnosis, global tularemia market is segmented into microscopy, immunochemistry, others.

On the basis of drugs, global tularemia market is segmented into streptomycin, gentamicin, doxycycline, ciprofloxacin, others.

On the basis of end user the global tularemia market is segmented into hospitals, clinics, academic & research institute.

On the basis of geography, global tularemia market report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others. In 2017, North America is expected to dominate the market.


Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *